• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Eisai - Articles and news items

benefit-sarcoma

Eisai bewildered as IQWIG fails to recognise OS benefit of liposarcoma drug

Industry news / 5 September 2016 / Niamh Louise Marriott, Digital Content Producer

n study 309, the pivotal phase III trial on which the indication approval was based, eribulin demonstrated a significant survival advantage in advanced liposarcoma; patients treated with eribulin compared to those treated with dacarbazine, a longstanding, established and internationally accepted treatment option, benefited from a median 7.2 month increase in overall survival for the pre-specified subgroup of patients with unresectable advanced or metastatic liposarcoma (15.6 months versus 8.4 months, HR = 0.511; 95% CI 0.346–0.753; P = 0.0006)…

cdf

Eisai calls for immediate solution to CDF black hole

Industry news / 8 July 2016 / Victoria White, Digital Content Producer

Eisai has expressed concern that patients in England and Wales will have to wait three years to access Lenvatinib due to a ‘black hole’ in the CDF process…

eribulin

The vascular remodelling effects of eribulin in advanced breast cancer

Industry news / 12 May 2016 / Victoria White, Digital Content Producer

Newly published data validate the distinct vascular remodelling activity of Halaven (eribulin) compared to bevacizumab in breast tumour tissue…

eribulin

EC approves eribulin for the treatment of advanced liposarcoma

Industry news / 5 May 2016 / Victoria White, Digital Content Producer

Eribulin is approved for those patients who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease…

eribulin

CHMP adopts positive opinion for eribulin in advanced liposarcoma

Industry news / 5 April 2016 / Victoria White

The European Medicines Agency’s CHMP has adopted a positive opinion for a licence extension for Eisai’s Halaven (eribulin)…

lenvatinib

Lenvatinib approved in Israel for patients with advanced thyroid cancer

Industry news / 9 March 2016 / Victoria White

From today, people in Israel with radioactive iodine refractory differentiated thyroid cancer will have access to Eisai’s Lenvima (lenvatinib)…

eisai

Eisai criticises NHSE for further delaying access to cancer treatments

Industry news / 26 February 2016 / Victoria White

New licensed drugs that have been denied access since May 2015 will have to wait until at least July 2016 before they can be considered for the new Cancer Drug Fund…

PQR309

New study to investigate PQR309 and eribulin in triple-negative breast cancer

Industry news / 17 February 2016 / Victoria White

Eisai and PIQUR Therapeutics are to collaborate to conduct the Phase I/IIb clinical study of PIQUR’s PQR309 in combination with Eisai’s eribulin…

eribulin

Results from eribulin study in liposarcomas and leiomyosarcomas published

Industry news / 11 February 2016 / Victoria White

Eisai’s Halaven (eribulin) is the first in the halichondrin class of microtubule dynamics inhibitors with a novel mechanism of action…

Halaven

FDA approves Eisai’s Halaven in liposarcoma

Industry news / 29 January 2016 / Victoria White

Halaven is the first and only single agent to demonstrate an overall survival benefit in a Phase III trial in patients with leiomyosarcoma or liposarcoma…

lenvatinib

Eisai’s lenvatinib receives FDA priority review

Industry news / 18 January 2016 / Victoria White

The FDA has accepted for Priority Review Eisai’s supplemental New Drug Application for lenvatinib for the potential treatment of patients with renal cell carcinoma…

lenvatinib

Eisai submits MAA for lenvatinib in renal cell carcinoma

Industry news / 12 January 2016 / Victoria White

Eisai has submitted the MAA to the EMA for the use of lenvatinib in combination with everolimus to treat people with unresectable advanced or metastatic renal cell carcinoma who have received one prior vascular endothelial growth factor targeted therapy…

 

Webinar: Different thermal analysis techniques to measure the glass transitionWATCH NOW
+ +